211 related articles for article (PubMed ID: 20660332)
1. Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma.
Durnick DK; Law ME; Maurer MJ; Natkunam Y; Levy R; Lossos IS; Kurtin PJ; McPhail ED
Am J Clin Pathol; 2010 Aug; 134(2):278-81. PubMed ID: 20660332
[TBL] [Abstract][Full Text] [Related]
2. Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma.
Nakamura S; Ye H; Bacon CM; Goatly A; Liu H; Kerr L; Banham AH; Streubel B; Yao T; Tsuneyoshi M; Savio A; Takeshita M; Dartigues P; Ruskoné-Fourmestraux A; Matsumoto T; Iida M; Du MQ
Clin Cancer Res; 2008 May; 14(10):3002-10. PubMed ID: 18445693
[TBL] [Abstract][Full Text] [Related]
3. The spectrum of B-cell non-Hodgkin lymphomas with dual IgH-BCL2 and BCL6 translocations.
Keller CE; Nandula S; Fisher J; Subramaniyam S; Vakiani E; Savage DG; Murty VV; Alobeid B; Bhagat G
Am J Clin Pathol; 2008 Aug; 130(2):193-201. PubMed ID: 18628087
[TBL] [Abstract][Full Text] [Related]
4. Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a "non-germinal center phenotype".
Kusumoto S; Kobayashi Y; Sekiguchi N; Tanimoto K; Onishi Y; Yokota Y; Watanabe T; Maeshima AM; Ishida T; Inagaki H; Matsuno Y; Ueda R; Tobinai K
Am J Surg Pathol; 2005 Aug; 29(8):1067-73. PubMed ID: 16006802
[TBL] [Abstract][Full Text] [Related]
5. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
[TBL] [Abstract][Full Text] [Related]
6. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
Obermann EC; Csato M; Dirnhofer S; Tzankov A
J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
[TBL] [Abstract][Full Text] [Related]
7. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.
Barrans SL; Evans PA; O'Connor SJ; Kendall SJ; Owen RG; Haynes AP; Morgan GJ; Jack AS
Clin Cancer Res; 2003 Jun; 9(6):2133-9. PubMed ID: 12796378
[TBL] [Abstract][Full Text] [Related]
8. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
[TBL] [Abstract][Full Text] [Related]
9. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
[TBL] [Abstract][Full Text] [Related]
10. The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma.
Ueda C; Akasaka T; Kurata M; Maesako Y; Nishikori M; Ichinohasama R; Imada K; Uchiyama T; Ohno H
Oncogene; 2002 Jan; 21(3):368-76. PubMed ID: 11821949
[TBL] [Abstract][Full Text] [Related]
11. Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma.
Dierlamm J; Murga Penas EM; Bentink S; Wessendorf S; Berger H; Hummel M; Klapper W; Lenze D; Rosenwald A; Haralambieva E; Ott G; Cogliatti SB; Möller P; Schwaenen C; Stein H; Löffler M; Spang R; Trümper L; Siebert R;
Haematologica; 2008 May; 93(5):688-96. PubMed ID: 18367485
[TBL] [Abstract][Full Text] [Related]
12. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
[TBL] [Abstract][Full Text] [Related]
13. Derivative (3)t(3;18)(q27;q21)t(18;16)(q21;?) involving the BCL2 and BCL6 genes in follicular lymphoma with t(3;14;18)(q27;q32;q21).
Yamamoto K; Ono K; Katayama Y; Shimoyama M; Matsui T
Cancer Genet Cytogenet; 2007 Nov; 179(1):69-75. PubMed ID: 17981218
[TBL] [Abstract][Full Text] [Related]
14. A novel t(3;8)(q27;q24.1) simultaneously involving both the BCL6 and MYC genes in a diffuse large B-cell lymphoma.
Wang HY; Bossler AD; Schaffer A; Tomczak E; DiPatri D; Frank DM; Nowell PC; Bagg A
Cancer Genet Cytogenet; 2007 Jan; 172(1):45-53. PubMed ID: 17175379
[TBL] [Abstract][Full Text] [Related]
15. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
[TBL] [Abstract][Full Text] [Related]
16. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.
Iqbal J; Greiner TC; Patel K; Dave BJ; Smith L; Ji J; Wright G; Sanger WG; Pickering DL; Jain S; Horsman DE; Shen Y; Fu K; Weisenburger DD; Hans CP; Campo E; Gascoyne RD; Rosenwald A; Jaffe ES; Delabie J; Rimsza L; Ott G; Müller-Hermelink HK; Connors JM; Vose JM; McKeithan T; Staudt LM; Chan WC;
Leukemia; 2007 Nov; 21(11):2332-43. PubMed ID: 17625604
[TBL] [Abstract][Full Text] [Related]
17. Molecular features of a new human lymphoma cell line carrying both BCL2 and BCL6 gene rearrangements.
Yonetani N; Akasaka T; Akasaka H; Ohno H; Okuma M; Miura I; Takahashi N; Miyanishi S; Okumura A; Muramatsu M; Fukuhara S
Oncogene; 1998 Aug; 17(8):971-9. PubMed ID: 9747876
[TBL] [Abstract][Full Text] [Related]
18. t(14;18)(q32;q21) involving IGH and MALT1 is uncommon in cutaneous MALT lymphomas and primary cutaneous diffuse large B-cell lymphomas.
Wongchaowart NT; Kim B; Hsi ED; Swerdlow SH; Tubbs RR; Cook JR
J Cutan Pathol; 2006 Apr; 33(4):286-92. PubMed ID: 16630178
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas.
Bai M; Agnantis NJ; Skyrlas A; Tsanou E; Kamina S; Galani V; Kanavaros P
Mod Pathol; 2003 May; 16(5):471-80. PubMed ID: 12748254
[TBL] [Abstract][Full Text] [Related]
20. Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas.
Martín-Subero JI; Odero MD; Hernandez R; Cigudosa JC; Agirre X; Saez B; Sanz-García E; Ardanaz MT; Novo FJ; Gascoyne RD; Calasanz MJ; Siebert R
Genes Chromosomes Cancer; 2005 Aug; 43(4):414-23. PubMed ID: 15852472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]